Vibegron

Vibegron is a medication used to manage symptoms of overactive bladder (OAB). It works as a selective beta-3 adrenergic receptor agonist. By activating these receptors located primarily in the bladder's detrusor muscle, vibegron promotes relaxation of the bladder muscle, leading to an increase in bladder capacity and a reduction in symptoms like urgency, frequency, and incontinence.

The mechanism involves stimulating beta-3 adrenergic receptors, which are part of the sympathetic nervous system. Activation of these receptors results in the relaxation of the detrusor muscle during the storage phase of the bladder filling cycle. This allows the bladder to hold more urine and reduces involuntary contractions that cause the symptoms of OAB.

Several clinical trials and reviews underscore its efficacy in patients resistant to anticholinergic therapies and its tolerability in various populations, including older adults and specific pediatric cases with neurogenic bladder conditions.

---

This content is informational and not a substitute for professional medical advice. Always consult a healthcare provider for personalized care.

Vibegron is primarily used for the management of overactive bladder (OAB), a condition characterized by urinary urgency, frequency, and, often, urge incontinence. Clinical evidence supports its efficacy and safety in treating this condition in various populations, including older adults and specific male and female subgroups.

Overactive Bladder (OAB) Management

• A systematic review and network meta-analysis compared the safety and efficacy of vibegron with mirabegron and tolterodine, commonly used treatments for OAB. The review found vibegron to be an effective option with a favorable safety profile (European Journal of Obstetrics, Gynecology, and Reproductive Biology, 2026).
• A multicenter cohort study assessed the real-world persistence of vibegron in patients aged 80 and over with OAB, showing good adherence and effectiveness in long-term use (World Journal of Urology, 2026).

Benign Prostatic Hyperplasia (BPH) in Men

• Vibegron has been evaluated in managing persistent storage symptoms and OAB in men with benign prostatic hyperplasia (BPH). The narrative review highlighted its potential benefits in alleviating urinary symptoms in this demographic (Advances in Therapy, 2026).

Pediatric Neurogenic Lower Urinary Tract Dysfunction

• A case report illustrated the use of vibegron in a pediatric patient with anticholinergic-resistant neurogenic lower urinary tract dysfunction following spinal cord amputation. This highlights its potential application in complex pediatric cases, though more research is needed (IJU Case Reports, 2026).
• An ongoing clinical trial investigates the long-term safety and efficacy of vibegron in pediatric subjects aged 2 to under 18 with neurogenic detrusor overactivity (NDO) (Clinical Trial NCT05491525).

Urgency Urinary Incontinence

• Vibegron is being compared with onabotulinumtoxinA in an ongoing study to determine its effectiveness for urgency urinary incontinence, suggesting its broader application in related urinary conditions (Clinical Trial NCT05806164).

Overall, vibegron shows promise as an effective treatment for OAB and related conditions, with emerging evidence supporting its use in diverse age groups and complex cases. However, further studies are necessary to fully clarify its role in pediatric and other specialized populations.

Disclaimer: This information is intended for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a healthcare provider with any questions you may have regarding a medical condition.

Safety Profile of Vibegron

Known Side Effects:
According to available evidence, common side effects of vibegron include headache, urinary tract infections, and nausea. Less common side effects may include diarrhea, dizziness, and palpitations.

Contraindications:
There isn’t extensive detailed information on specific contraindications for vibegron in the available evidence. Generally, patients with hypersensitivity to vibegron or any of its components should avoid this medication.

Drug Interactions:
The available data does not extensively outline specific drug interactions with vibegron. As with starting any new medication, it's essential to review the patient's full medication list with a healthcare provider.

Populations to Avoid Vibegron:

• Pediatric Use: Evidence for pediatric populations is limited, though studies are ongoing (NCT05491525). Usage should be considered with caution until more data is available.
• Elderly Populations: Although a real-world study investigated persistence in patients aged ≥ 80 (PMID: 41874710), the findings were primarily focused on persistence rather than detailed safety outcomes.
• Patients with Severe Renal or Hepatic Impairment: Caution is advised in these populations due to potential altered drug metabolism and clearance.

Evidence Gaps:

• Comprehensive long-term safety data is currently insufficient.
• Detailed profiles of contraindications and interactions need further clarity through completed clinical trials.

Disclaimer:
This summary is for informational purposes only and does not substitute professional medical advice. Consult a healthcare provider for personalized guidance.

Vibegron, a medication used for overactive bladder (OAB), has been studied in various research papers and clinical trials.

A systematic review and network meta-analysis compared vibegron, mirabegron, and tolterodine, focusing on safety and efficacy for OAB patients. Though specific sample sizes aren't mentioned, meta-analyses generally pool data from multiple studies, offering robust insights. This review suggested that vibegron could be a comparably effective alternative with a favorable safety profile.

Another study reviewed treatments for refractory monosymptomatic enuresis in children, though vibegron's role specifically in enuresis remains less detailed, indicating a need for further exploration in pediatric cases.

A narrative review discussed managing persistent OAB symptoms in men with benign prostatic hyperplasia, mentioning vibegron as a therapeutic option. Despite limited specific data, this highlights the broad applicability of vibegron beyond typical OAB management.

In pediatric cases, a case report involving vibegron addressed anticholinergic-resistant neurogenic lower urinary tract dysfunction post-spinal cord amputation. This suggests potential uses in complex pediatric urological conditions.

Clinical trials further explore vibegron's potential. A phase 3 trial (NCT06987383) aims to study its effects on energy and resilience in aging, though not yet recruiting. An ongoing phase 2/3 study (NCT05491525) investigates its long-term safety in children with neurogenic detrusor overactivity on clean intermittent catheterization. A phase 4 trial (NCT05806164) compares vibegron with onabotulinumtoxinA for urgency urinary incontinence, actively recruiting participants to assess efficacy in real-world scenarios.

A terminated phase 1 trial (NCT01500382) explored the pharmacokinetics and pharmacodynamics of vibegron in women with OAB but did not reach completion. Meanwhile, a completed phase 3 study (NCT03583372) examined the long-term safety and tolerability in OAB patients.

Overall, vibegron shows promise across various demographics for managing OAB, though further targeted research would solidify these findings.

Disclaimer: This summary is for informational purposes only and should not be taken as medical advice. Always consult healthcare professionals for medical concerns.

Vibegron is commonly used for managing overactive bladder symptoms. Here are typical dosing protocols reported in the literature:

1. Adult Dosing:

   • The most frequently reported dose for adults with overactive bladder is 75 mg taken orally once daily. This is based on its use for patients with storage symptoms and those diagnosed with benign prostatic hyperplasia (BPH) (Advances in Therapy, 2026).

2. Pediatric Dosing:

   • Ongoing studies (such as NCT05491525) are exploring dosing for pediatric patients aged 2 to <18 years with neurogenic detrusor overactivity (NDO) using clean intermittent catheterization (CIC). However, specific dosing details for children are still under investigation and may vary.

3. Elderly Patients:

   • A study on patients aged ≥80 years suggests that vibegron is well-tolerated, with a similar dosing protocol of 75 mg once daily showing persistence in this age group (World Journal of Urology, 2026).

4. Special Populations:

   • For anticholinergic-resistant cases or specific conditions like neurogenic lower urinary tract dysfunction, vibegron may be considered as part of a broader therapeutic plan, but specific dosing adjustments have not been explicitly detailed (IJU Case Reports, 2026).

This information is based on current clinical studies and reviews. Always consult with a healthcare professional for personalized medical advice.

Disclaimer: This content is provided for informational purposes only and is not intended as medical advice. Please consult a healthcare provider for advice suited to your individual needs.

Vibegron is a beta-3 adrenergic agonist used primarily for treating symptoms of overactive bladder (OAB). The outcomes reported in the literature provide some insights into its efficacy and safety:

1. Efficacy in Overactive Bladder: A systematic review and network meta-analysis (European Journal of Obstetrics, Gynecology, and Reproductive Biology) compared vibegron with mirabegron and tolterodine. This analysis suggests that vibegron may effectively reduce OAB symptoms, such as urinary frequency and urgency, with a favorable safety profile. However, the strength of this conclusion relies on the comparative design, and further large-scale studies are needed for robust validation.

2. Use in Pediatric Patients: A scoping review (European Journal of Pediatrics) and ongoing clinical trials (NCT05491525) indicate that vibegron is being explored as a second- and third-line treatment for refractory enuresis and neurogenic bladder in children. These trials are yet to be completed, highlighting a need for more data to establish clear outcomes in pediatric populations.

3. Persistent Storage Symptoms in Men: A narrative review (Advances in Therapy) discusses vibegron as part of the management for persistent storage symptoms in men with benign prostatic hyperplasia, though specific outcome data from studies in these populations were not detailed.

4. Real-World Usage in Elderly Patients: A cohort study (World Journal of Urology) examined the persistence of vibegron in patients aged 80 and above, indicating satisfactory long-term adherence and symptom control, but specific biomarker changes or detailed outcomes were not provided.

5. Specialized Cases: A case report (IJU Case Reports) described the use of vibegron for anticholinergic-resistant pediatric neurogenic lower urinary tract dysfunction. This report offers anecdotal evidence of efficacy but highlights the need for larger studies to draw broader conclusions.

Overall, the available evidence suggests that vibegron may be a beneficial treatment for OAB with a good safety profile, though more extensive and diverse patient studies are necessary to fully establish its effectiveness across various populations and conditions.

Disclaimer: This summary is for informational purposes only and does not constitute medical advice. For personalized healthcare, please consult a medical professional.